ID 520 -
Kwas dokozaheksaenowy, Kwas eikozapentaenowy
PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid
Oświadczenie (2)
- układ odpornościowy
- układu odpornościowego
1. Charakterystyka żywności / składnika
The food constituent which is the subject of the health claims is mixed long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFA), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA) and, for ID 703, with docosapentaenoic acid (DPA).
The n-3 LCPUFA EPA, DHA and DPA are recognised nutrients and are measurable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA, DHA and, for ID 703, DPA from all sources with suitable bioavailability in the specified amounts.
The Panel considers that the food constituent, EPA, DHA and DPA, which is the subject of the health claims, is sufficiently characterised.
2.9. Wpływ na prawidłowe funkcjonowanie układu odpornościowego poprzez zmniejszenie mediatorów stanu zapalnego (pochodnych kwasu arachidonowego) i cytokin prozapalnych (ID 520, 2914)
The claimed effects are “immune function” and “normal immune system function”. The target population is assumed to be the general population.
From the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effect refers to supporting a normal/healthy immune function in the context of decreasing the level or production of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines.
Inflammation is a non-specific physiological response to tissue damage that is mediated by the immune system. Adequate inflammatory responses are of primary importance for the defence against injury of any origin. Changes in markers of inflammation such as decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines do not indicate a beneficial physiological effect per se.
Chronic inflammation is associated with a number of diseases, and under certain circumstances reducing levels of markers of inflammation might indicate a beneficial physiological effect.
Whether or not reduction of inflammatory markers is considered beneficial would depend on the context in which the claim is made. The Panel considers that the evidence provided does not define the context whereby decreasing the level or production of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines might be a beneficial physiological effect in the general healthy population.
The Panel concludes that a cause and effect relationship has not been established between the consumption of DHA and EPA and a beneficial physiological effect related to the contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid- derived mediators and pro-inflammatory cytokines.
Warunki i możliwe ograniczenia stosowania oświadczenia
5-10ml per day